PRESS RELEASE: 'Corporate Reputation of Pharma, 2018 - the Perspective of Patient Groups Specialising in Neurological Conditions' 'Corporate Reputation of Pharma in 2018 - the Perspective of Neurological Patient Groups' ~ Contact: Alex Wyke ~ Tel: +44-(0)7960-855-019 ~ Email: report@patient-view.com EMBARGO: London, September 9th, 2019 6AM GMT ABOUT THIS REPORT AND SURVEY
AbbVie | Acorda | Allergan | Almirall | Amgen | Astellas | AstraZeneca | Bayer | Bial | Biogen | Boehringer Ingelheim | Bristol-Myers Squibb | Celgene | Eisai | Eli Lilly | Grünenthal | GSK | Ipsen | Lundbeck | Merck & Co/MSD | Merck KGaA/EMD Serono | Novartis | Novo Nordisk | Pfizer | Roche/Genentech | Sanofi | Servier | Takeda/Shire | Teva | and UCB. The 2018 'Corporate-Reputation' neurological report contains four appendices:
And ... Appendix IV: Comments from 2018's respondent neurological patient groups on how pharma can improve (organised by country and condition). KEY FINDINGS ACROSS THE PHARMA INDUSTRY The corporate reputation of the pharmaceutical industry, 2013-2018. Percentage of respondent neurological patient groups each year stating “Excellent” or “Good”
The 222 neurological patient groups worldwide responding to the 2018 'Corporate Reputation of the Pharmaceutical Industry' survey were more negative about the industry’s corporate reputation than their predecessor respondents in 2017. A total of 37% of 2018’s 222 neurological patient groups stated that the pharma industry as a whole had an “Excellent” or “Good” corporate reputation in 2018—ranking the industry 4th for corporate reputation out of nine healthcare sectors (compared with 3rd in 2017). However, the chart above shows just how sentiment about the industry has fluctuated among neurological patient groups, year to year. Percentage of respondent neurological patient groups, per year, stating that the pharmaceutical industry is “Excellent” or “Good” at providing high-quality useful products One possible explanation for the industry’s fall in corporate reputation among neurological patient groups during 2018 is that these groups (and patients with a neurological condition) regard pharma’s ability to innovate, and to produce useful new neurological products, to be at its lowest since 2015. The different categories of neurological patient groups take diverse attitudes to pharma's corporate reputation—although these patient groups unilaterally marked the industry down in 2018 [see chart below]. Nonetheless, the categories of neurological patient groups that are the most positive about pharma's ability to create useful, high-quality products are also those which rate the corporate reputation of the industry most highly. Percentage of various categories of neurological patient groups stating that the pharmaceutical industry as a whole had an “Excellent” or “Good” corporate reputation, 2018 v. 2017 Percentage of various categories of neurological patient groups stating that the pharmaceutical industry as a whole was “Excellent” or “Good” at providing high-quality products useful to patients, 2018 v. 2017 Feedback received from 2018's respondent neurological patient groups indicates that many are concerned about both pricing and access to the innovative medicines which do happen to be available.
“Continue to focus on delivering real innovation, and not ‘me-too’ products. Companies also must address the price of innovative medicines in the US.”
“Keep the medication low tech, easily available, and easy to access for patients—unlike some of the new treatments, which are high tech, extremely expensive, and need the patient to be seen in more than just primary care.”
HOW DID COMPANIES PERFORM? HOW CORPORATE REPUTATION IS MEASURED The overall corporate reputation of each company is assessed according to that company's performance (as judged by neurological patient groups) at 12 individual indicators of corporate reputation. The TOP-TEN companies for corporate reputation—from the perspective of neurological patient groups familiar with the company, 2018 v. 2017 The indicators [listed below] have been developed over the years by PatientView, drawing on recommendations from patient groups, health professionals, health regulators, and industry. PatientView's 12 indicators used to assess pharma corporate reputation
UCB dominated the neurological corporate-reputation league tables for 2018, coming overall 1st out of 30 companies (as it did in 2017), and 1st for 7 of the 12 individual indicators of corporate reputation—according to the 46 respondent neurological patient groups familiar with the company.
Acorda Therapeutics saw the biggest increase up the rankings, coming 9th out of 30 companies in 2018—up ten places from its 2017 position. The EPILEPSY corporate-reputation rankings, 2018 [32 respondent epilepsy patient groups]Companies ranking 1st out of 6 companies among epilepsy patient groups familiar with the company, 2018 UCB was ranked overall 1st for corporate reputation in 2018 by epilepsy patient groups familiar with the company
The MULTIPLE-SCLEROSIS corporate-reputation rankings, 2018 [45 respondent MS patient groups]Companies ranking 1st out of 8 companies among multiple-sclerosis patient groups familiar with the company, 2018 Sanofi was ranked overall 1st for corporate reputation in 2018 by multiple-sclerosis patient groups familiar with the company
The PARKINSON'S-DISEASE corporate-reputation rankings, 2018 [29 respondent Parkinson's patient groups]Companies ranking 1st out of 6 companies among Parkinson's patient groups familiar with the company, 2018 AbbVie was ranked overall 1st for corporate reputation in 2018 by Parkinson's patient groups familiar with the company
-END OF PRESS RELEASE- For further information on the 2018 NEUROLOGICAL report, please use contact details at the top of this press release ~END OF PRESS RELEASE~
|